Dennis Mulroy was named Chief Financial Officer of Arcturus Therapeutics Holdings Inc., effective May 1, 2026. As of November 6, 2026, Arcturus Therapeutics Holdings Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 7, 2026, naming 2 appointments (Form 8-K, May 7, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Arcturus Therapeutics Holdings Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Arcturus Therapeutics Holdings Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-07. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Arcturus Therapeutics Holdings Inc. files it.
Also on the record for Arcturus Therapeutics Holdings Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 29, 2026 | Stake report, Schedule 13G/A, by Sumitomo Mitsui Trust Group, Inc. | 5.9% of the class | 5%+ stakes | Source |
| October 7, 2026 | Stake report, Schedule 13G/A, by Federated Hermes, Inc. | 5.9% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 10.37% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Balyasny Asset Management L.P. | — | 5%+ stakes | Source |
| February 3, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 9.19% of the class | 5%+ stakes | Source |
| January 8, 2026 | Stake report, Schedule 13G/A, by Federated Hermes, Inc. | 11.63% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Balyasny Asset Management L.P. | 8.04% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Amova Asset Management Americas, Inc. | 7.2% of the class | 5%+ stakes | Source |
| October 27, 2025 | Stake report, Schedule 13G/A, by Sumitomo Mitsui Trust Group, Inc. | 7.2% of the class | 5%+ stakes | Source |
| July 30, 2025 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 6.32% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 6.67% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Arcturus Therapeutics Holdings Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Arcturus Therapeutics Holdings Inc. and the records around it.
Arcturus Therapeutics Holdings Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Amova Asset Management Americas, Inc. also filed stake reports on 3 other companies: Ibotta, Inc. (Feb 2026), 10x Genomics, Inc. (Nov 2025)
- Sumitomo Mitsui Trust Group, Inc. also filed stake reports on 7 other companies: GCM Grosvenor Inc. (Apr 2026), Ibotta, Inc. (Feb 2026), 10x Genomics, Inc. (Oct 2025)
- Federated Hermes, Inc. also filed stake reports on 13 other companies: EyePoint (Nov 2026), Forte Biosciences, Inc. (Sep 2026), SCYNEXIS INC (Jul 2026)
Watch Arcturus Therapeutics Holdings Inc.
Get an email when Arcturus Therapeutics Holdings Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Arcturus Therapeutics Holdings Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Arcturus Therapeutics Holdings Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arcturus Therapeutics Holdings Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-07 | In | Chief Financial Officer | 2026-05-01 | 8-K, 2026-05-07 | |
| 2026-05-07 | In | 8-K, 2026-05-07 |
Who leads Arcturus Therapeutics Holdings Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Dennis Mulroy, appointed, effective 2026-05-01 (filed 2026-05-07).
New leaders reset buying decisions — get the Full Report on Arcturus Therapeutics Holdings Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Arcturus Therapeutics Holdings Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Arcturus Therapeutics Holdings Inc.Every change, in the filing's words
Appointed: Dennis Mulroy, Chief Financial Officer, effective 2026-05-01
Effective May 1, 2026, Dennis Mulroy, 71, was appointed Chief Financial Officer of the Company.
Appointed: Dennis Mulroy
Mr. Mulroy will become the Company's principal financial officer on the date immediately following the date on which the Company files its Quarterly Report on Form 10-Q for the period ended March 31, 2026.
- The Board of Directors of the Company approved Mr. Mulroy's appointment on April 15, 2026.
- Mr. Mulroy served as the Chief Financial Officer of AnaptysBio, Inc from July 2020 to April 2026.
- From April 2015 to May 2020, Mr. Mulroy served as Chief Financial Officer of La Jolla Pharmaceutical Company.
- From 2005 to 2015, Mr. Mulroy served as Chief Financial Officer of Taxus Cardium Pharmaceuticals Group, Inc. From 2004 to 2005, Mr. Mulroy served as Chief Financial Officer of Molecular Imaging, Inc. Mr. Mulroy began his career at Ernst & Young LLP.
- Mr. Mulroy received a B.B.A. degree in accounting from the University of San Diego and is a Certified Public Accountant (inactive) in the state of California.
- The Employment Agreement provides that Mr. Mulroy's employment is at-will.
- In the event Mr. Mulroy's employment is terminated by the Company without Cause or Mr. Mulroy resigns for Good Reason (each as defined in the Employment Agreement), and subject to his execution of a general release of claims, Mr. Mulroy will be entitled to (i) continuation of his base salary for twelve (12) months, (ii) a pro rata portion of his annual bonus for the year of termination based on actual performance, and (iii) payment of COBRA premiums for up to twelve (12) months.
Tools for this story
Each opens in a new tab, filled in for Arcturus Therapeutics Holdings Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.